Article
[Annual therapeutic advances in advanced non-small cell lung cancer in 2024].
Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases - 12 Jan 2025
Luan T, Shen P X, Zhang Y H, Xie X H, Lin X Q, Liu M, Peng J, Deng H Y, Wang S Y, Wang C C, Zhou C Z
Abstract excerpt
This paper reviews the clinical progress achieved in 2024 in the field of advanced non-small cell lung cancer (NSCLC), both nationally and internationally. In the area of targeted therapy, particularly for rare mutations, new targets beyond EGFR, ALK, and ROS1 mutations, such as KRAS G12C, HER2, and MET, have gained more clinical validation and approval for targeted drugs in 2024. KRAS G12C inhibitors have also...
Topics
Join the communities discussing this publication.